Literature DB >> 9517607

Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular-weight heparin.

J F Molinari1, C Campo, S Shakir, T Ahmed.   

Abstract

Unfractionated heparin (UF-heparin) has been shown to prevent antigen-induced airway hyperresponsiveness (AHR), but it is ineffective when administered after the antigen challenge. We hypothesized that the failure of UF-heparin to modify postantigen AHR might depend on molecular weight. We therefore studied the effects of UF-heparin and three low-molecular-weight heparin fractions (medium-molecular-weight heparin [MMWH]; low-molecular-weight heparin [LMWH]; and ultralow-molecular-weight heparin [ULMWH]) on antigen-induced AHR and histamine release in bronchoalveolar lavage fluid (BALF). Specific lung resistance (SRL) was measured in 20 allergic sheep before, immediately after, and up to 2 h after challenge with Ascaris suum antigen. Airway responsiveness was expressed as the cumulative provocative dose of carbachol, in breath units, that increased SRL by 400% (PD400). PD400 was determined before and 2 h after antigen, both without and after treatment with aerosolized UF-heparin (1,000 U/kg) and various heparin fractions (0.04 mg/kg to 5 mg/kg) administered after the antigen challenge. Inhaled UF-heparin (n = 4), MMWH (n = 4), and LMWH (n = 6) failed to modify postantigen AHR when administered after the challenge. Only ULMWH (n = 6) inhibited postantigen AHR in a dose-dependent manner (percent protection ranged from 31% to 139%). In eight additional sheep, histamine in BALF was measured with a radioimmunoassay (RIA) before and after the segmental antigen challenge, without and after pretreatment with inhaled UF-heparin, LMWH, or ULMWH. Inhaled UF-heparin and LMWH inhibited antigen-induced histamine release as measured in BALF by 81% and 75%, respectively; whereas ULMWH was ineffective in this respect. We conclude that: (1) modification of antigen-induced AHR by fractionated heparins is molecular-weight dependent; and (2) only ULMWH attenuates AHR when administered after antigen challenge, via an unknown mast-cell-independent action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517607     DOI: 10.1164/ajrccm.157.3.9708027

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  3 in total

1.  Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-11-28       Impact factor: 2.849

2.  Heparin normalizes allergen-induced nitric oxide deficiency and airway hyperresponsiveness.

Authors:  Harm Maarsingh; Jacob de Boer; Henk F Kauffman; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

Review 3.  Pharmacological factors that influence the choice of inhaled corticosteroids.

Authors:  S Edsbäcker
Journal:  Drugs       Date:  1999       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.